pI: 6.2114 |
Length (AA): 375 |
MW (Da): 43540 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Ortholog group members (OG5_132040)
Species | Accession | Gene Product |
---|---|---|
Echinococcus granulosus | EgrG_000871500 | coiled coil domain containing protein 96 |
Echinococcus multilocularis | EmuJ_000871500 | coiled coil domain containing protein 96 |
Giardia lamblia | GL50803_22806 | Hypothetical protein |
Homo sapiens | ENSG00000173013 | coiled-coil domain containing 96 |
Leishmania braziliensis | LbrM.14.0210 | hypothetical protein, conserved |
Leishmania donovani | LdBPK_140210.1 | Domain of unknown function (DUF4201), putative |
Leishmania infantum | LinJ.14.0210 | hypothetical protein, conserved |
Leishmania major | LmjF.14.0210 | hypothetical protein, conserved |
Leishmania mexicana | LmxM.14.0210 | hypothetical protein, conserved |
Mus musculus | ENSMUSG00000050677 | coiled-coil domain containing 96 |
Neospora caninum | NCLIV_003450 | ankyrin repeat-containing protein, putative |
Schistosoma japonicum | Sjp_0301580 | Coiled-coil domain-containing protein 113, putative |
Schistosoma mansoni | Smp_014680 | hypothetical protein |
Schmidtea mediterranea | mk4.006225.02 | |
Schmidtea mediterranea | mk4.001174.07 | |
Schmidtea mediterranea | mk4.000013.12 | |
Schmidtea mediterranea | mk4.033587.00 | |
Trypanosoma brucei gambiense | Tbg972.7.5110 | hypothetical protein, conserved |
Trypanosoma brucei | Tb11.v5.0264 | Domain of unknown function (DUF4201), putative |
Trypanosoma congolense | TcIL3000_7_3740 | Domain of unknown function (DUF4201), putative |
Trypanosoma cruzi | TcCLB.506605.90 | Domain of unknown function (DUF4201), putative |
Trypanosoma cruzi | TcCLB.511239.80 | Domain of unknown function (DUF4201), putative |
Toxoplasma gondii | TGME49_209040 | hypothetical protein |
Trichomonas vaginalis | TVAG_055930 | mus musculus adult male testis cDNA, riken full-length enriched library, clone:4, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.7.4510 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.7.4510 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.7.4510 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.7.4510 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
TGME49_209040 | Toxoplasma gondii | Probably non-essential | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.